← Back to Screener
Schrodinger, Inc. Common Stock (SDGR)
Price$14.38
Value ScoreC
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-26.03%
Price vs S&P 500 (4W)9.53%
VGM Score46.72
Market Capitalization$1.07B
All Metrics
P/CF (Annual)77.31x
Book Value / Share (Quarterly)$4.21
P/TBV (Annual)4.70x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)12.23%
Cash Flow / Share (Quarterly)$-1.99
Price vs S&P 500 (YTD)-27.73%
Gross Margin (TTM)55.33%
Net Profit Margin (TTM)-40.60%
EPS (TTM)$-1.40
10-Day Avg Trading Volume1.60M
EPS Excl Extra (TTM)$-1.40
Revenue Growth (5Y)18.81%
EPS (Annual)$-1.41
ROI (Annual)-28.37%
Gross Margin (Annual)55.74%
Net Profit Margin (5Y Avg)-53.39%
Cash / Share (Quarterly)$5.35
Revenue Growth QoQ (YoY)-1.62%
ROA (Last FY)-14.22%
Revenue Growth TTM (YoY)10.59%
EBITD / Share (TTM)$-2.16
ROE (5Y Avg)-23.34%
Operating Margin (TTM)-64.65%
Cash Flow / Share (Annual)$0.17
P/B Ratio3.43x
P/B Ratio (Quarterly)2.67x
Net Income / Employee (Annual)$-121,500
EV / Revenue (TTM)3.19x
Net Interest Coverage (TTM)-63.83x
ROA (TTM)-15.32%
EPS Incl Extra (Annual)$-1.41
Current Ratio (Annual)2.75x
Quick Ratio (Quarterly)2.68x
3-Month Avg Trading Volume1.47M
52-Week Price Return-39.68%
EV / Free Cash Flow (Annual)65.36x
Revenue / Employee (TTM)$299,900
Tangible BV / Share (Quarterly)$7.60
P/S Ratio (Annual)4.20x
Asset Turnover (Annual)0.35x
52-Week High$27.63
Operating Margin (5Y Avg)-81.97%
EPS Excl Extra (Annual)$-1.41
CapEx CAGR (5Y)-10.71%
Tangible BV CAGR (5Y)64.36%
26-Week Price Return-18.11%
Quick Ratio (Annual)2.68x
13-Week Price Return10.36%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.74x
Enterprise Value$814.23M
Revenue / Share Growth (5Y)14.10%
Asset Turnover (TTM)0.38x
Book Value / Share Growth (5Y)-11.16%
Revenue / Employee (Annual)$301,000
Pretax Margin (Annual)-39.99%
Cash / Share (Annual)$5.37
3-Month Return Std Dev52.69%
Gross Margin (5Y Avg)57.54%
Net Income / Employee (TTM)$-121,700
ROE (Last FY)-28.37%
Net Interest Coverage (Annual)-4.51x
EPS Basic Excl Extra (Annual)$-1.41
Receivables Turnover (TTM)5.58x
EV / Free Cash Flow (TTM)46.68x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.40
Receivables Turnover (Annual)1.44x
ROI (TTM)-30.85%
P/S Ratio (TTM)4.22x
Pretax Margin (5Y Avg)-53.03%
Revenue / Share (Annual)$3.48
Tangible BV / Share (Annual)$7.60
Free OCF CAGR (5Y)-2.61%
Price vs S&P 500 (52W)-64.05%
Year-to-Date Return-19.57%
5-Day Price Return-8.99%
EPS Normalized (Annual)$-1.41
ROA (5Y Avg)-13.36%
Net Profit Margin (Annual)-40.36%
Month-to-Date Return-5.39%
Cash Flow / Share (TTM)$0.68
EBITD / Share (Annual)$-2.19
Operating Margin (Annual)-65.23%
P/CF (TTM)69.74x
ROI (5Y Avg)-23.34%
EPS Basic Excl Extra (TTM)$-1.40
P/TBV (Quarterly)4.70x
P/B Ratio (Annual)3.62x
Pretax Margin (TTM)-40.08%
Book Value / Share (Annual)$4.94
Price vs S&P 500 (13W)2.11%
Beta1.64x
P/FCF (Annual)86.26x
Revenue / Share (TTM)$3.45
ROE (TTM)-30.85%
52-Week Low$10.95
vGradeC
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.81est. -0.65
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.13
4.07
4.07
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SDGRSchrodinger, Inc. Common Stock | C | C | C | $14.38 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Schrodinger is a software platform company that helps pharmaceutical, biotech, and materials science organizations accelerate molecular discovery and optimization. The company operates two segments: a Software segment that licenses its computational platform to enterprise customers (the primary revenue source), and a Drug Discovery segment that develops internal and collaborative preclinical and clinical programs. The United States represents the company's largest geographic market.